Gyre Therapeutics Inc (GYRE) Unusual Options Activity Today

Checking GYRE unusual options activity helps you spot when traders are making outsized bets on Gyre Therapeutics Inc before the broader market catches on. Gyre Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor GYRE unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching GYRE unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking GYRE unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and GYRE unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Catalysts rarely arrive without a footprint, and GYRE unusual options activity is often where that footprint shows up first. Our scanner tracks Gyre Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at GYRE unusual options volume on the call side or chasing put sweeps, Gyre Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.